In addition, c-MET overexpression is observed in 20-48% of human HCC samples [18-20] and where it may be a predictor for sensitivity to agents such as the tyrosine kinase inhibitor sorafenib [21]. The gene discussed is MET; the disease is hepatocellular carcinoma.